Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Eclipsebio, Element Biosciences, Precipio

Eclipsebio eRibo Pro Service

Eclipsebio has launched its eRibo Pro service to identify differential transcription and translation as well as high-resolution mapping of ribosome positioning. Customers receive an interactive report with two data sets from a single sample: a ribosome-protected fragment library and an RNA-seq library. These data are intended to enable researchers to, for instance, quantify changes in transcription and translation in response to therapeutics, the San Diego-based company notes on its website. eRibo Pro incorporates exclusively licensed Ribo-seq technology developed by researchers at the University of California, San Francisco, the company noted.

Element Biosciences Aviti FIT Suite

Element Biosciences has launched Aviti Fit, a suite of products to provide more flexibility on its Aviti instrument.

The Aviti LT (low-throughput) is an instrument configured to run only low- and medium-throughput sequencing kits. It can be upgraded later to run the full lineup of kits. New sequencing kits include a 1 billion-read 2x75 bp kit, 250 million- and 500 million-read 2x150 bp kits, and 300 million- and 100 million-read 2x300 bp kits. Some new kits will offer two individually addressable lanes.

The firm is also launching Elembio Cloud, an online platform for managing instruments, monitoring runs with real-time updates, and visualizing run metrics and data to gauge run performance.

Precipio Quantitative BCR-ABL 2.0 Panel

Precipio has launched its Quantitative BCR-ABL 2.0 panel for confirming a chronic myeloid leukemia (CML) diagnosis. According to the New Haven, Connecticut-based firm, CML patients have cells containing the BCR-ABL1 gene, which creates a hybrid protein resulting in uncontrolled cell division and genomic instability. The presence of the gene confirms CML diagnosis and can be used to monitor patients and their response to various therapies. The test provides quantitative coverage of four clinically relevant breakpoints, p.190, p.210, p.203, and p.230, and the panel comes with automated analysis software, Precipio said.

For more new products and services, please visit the New Products page on our website.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.